64th American Society of Hematology Annual Meeting and Exposition (ASH 2022)

Blinatumomab-chemo boosts survival in MRD-negative B-lineage ALL

Roshini Claire Anthony, 20230208180001

The addition of blinatumomab to chemotherapy extended overall survival (OS) in adults with measurable residual disease (MRD)-negative B-lineage acute lymphoblastic leukaemia (ALL), according to results of the phase III ECOG-ACRIN E1910 trial.

Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?

Roshini Claire Anthony, 20230206150001

The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.

Durable benefits with beti-cel therapy in beta-thalassaemia

Elvira Manzano, 20230126000000

One-time ex-vivo gene therapy with betibeglogene autotemcel (beti-cel) reduces the need for transfusion in patients with transfusion-dependent beta-thalassaemia in an analysis of studies presented at ASH 2022.

Efgartigimod tied to sustained platelet count increase in patients with ITP

Elaine Soliven, 20230124000000

Treatment with efgartigimod, a neonatal Fc receptor (FcRn) antagonist, in patients with chronic or persistent immune thrombocytopenia (ITP) resulted in a higher proportion of patients achieving a sustained platelet count response compared with placebo, according to the ADVANCE IV* trial presented at ASH 2022.

Device filters out direct thrombin inhibitor from plasma for routine haemostasis tests

Jairia Dela Cruz, 20230123080000

A user-friendly medical device can effectively remove the direct thrombin inhibitor (DTI) argatroban from plasma in a rapid and ergonomic manner, as shown in the results of a study presented at ASH 2022.

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

Stephen Padilla, 20230120120000

Use of FRSW 107, a novel homodimer recombinant factor VIII (rFVIII) Fc fusion protein, for prophylaxis and treatment of bleeding episodes is both safe and effective among previously treated adolescent and adult patients with haemophilia A (HA), reports a China study presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

Jairia Dela Cruz, 20230120090000

Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.

Mitapivat maintains long-term Hb response in PK deficiency patients

Stephen Padilla, 20230119120000

Treatment with mitapivat results in long-term and durable improvements in haemoglobin (Hb) and a decrease in transfusion burden over several years in patients with pyruvate kinase (PK) deficiency, according to the results of a study, which was presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

It’s time to do away with neutropenic diet post-HSCT – experts

Elvira Manzano, 20230117000000

Adopting a low-microbial, protective (neutropenic) diet offers no clear benefit to patients following hematopoietic stem cell transplantation (HSCT) in a study described as the first to investigate the role of neutropenic diet post-HSCT.

$PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib$

PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib

Roshini Claire Anthony, 20230115100001

The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.